Befejeződött2. fázis
68Ga satoreotide trizoxetan PET/CT in patients with high grade neuroendocrine lung cancer
Key facts
- Where
- Copenhagen Oe, DániaSee the site
- Phase
- 2. fázis
Where in Dánia
- RigshospitaletCopenhagen Oe, DániaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rigshospitalet
- Trial code
- EU 2023-503362-24-01
- Record updated
- 2023. május 10.
- Original description
The aim of this study is to investigate the uptake of the new positron emission tomography (PET-)tracer 68Ga-satoreotide trizoxetan in patients with high-grade neuroendocrine lung cancer.Read full original descriptionShow less
The aim of this study is to investigate the uptake of the new positron emission tomography (PET-)tracer 68Ga-satoreotide trizoxetan in patients with high-grade neuroendocrine lung cancer.
Inclusion: Pathologically verified SCLC or LCNEC; Age ≥ 18 years; Informed oral and written consent.
Exclusion: Previous radiotherapy to target lesions in the lungs; Previous or current treatment with somatostatin analogues; Current complete response to therapy; Carcinoid syndrome; Other active malignancy, except for non-melanoma skin cancer; Allergy to somatostatin analogues; Unknown primary tumor; Pregnancy or lactation; Communication difficulties, including inability to understand the oral and/or written study material.